Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:LEGN NASDAQ:SVRA NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.84+0.0%$23.23$19.69▼$28.35$4.25B0.81.73 million shs1.05 million shsLEGNLegend Biotech$22.22-5.6%$28.87$16.24▼$44.17$4.37B0.341.84 million shs1.69 million shsSVRASavara$5.51-4.2%$5.53$2.43▼$7.01$1.18B0.241.90 million shs1.55 million shsVKTXViking Therapeutics$34.79-1.7%$33.79$22.96▼$43.15$4.11B0.662.27 million shs1.84 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+0.04%-2.97%+6.34%+13.11%+6.75%LEGNLegend Biotech-5.57%-0.18%-24.37%-7.03%-49.86%SVRASavara-4.17%-0.18%-5.49%+7.62%+121.29%VKTXViking Therapeutics-1.70%-6.18%-8.13%+6.23%+4.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.84+0.0%$23.23$19.69▼$28.35$4.25B0.81.73 million shs1.05 million shsLEGNLegend Biotech$22.22-5.6%$28.87$16.24▼$44.17$4.37B0.341.84 million shs1.69 million shsSVRASavara$5.51-4.2%$5.53$2.43▼$7.01$1.18B0.241.90 million shs1.55 million shsVKTXViking Therapeutics$34.79-1.7%$33.79$22.96▼$43.15$4.11B0.662.27 million shs1.84 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+0.04%-2.97%+6.34%+13.11%+6.75%LEGNLegend Biotech-5.57%-0.18%-24.37%-7.03%-49.86%SVRASavara-4.17%-0.18%-5.49%+7.62%+121.29%VKTXViking Therapeutics-1.70%-6.18%-8.13%+6.23%+4.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.67Moderate Buy$33.1733.52% UpsideLEGNLegend Biotech 2.50Moderate Buy$55.38149.26% UpsideSVRASavara 2.88Moderate Buy$10.1484.08% UpsideVKTXViking Therapeutics 2.67Moderate Buy$97.00178.82% UpsideCurrent Analyst Ratings BreakdownLatest SVRA, ACAD, LEGN, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026LEGNLegend Biotech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$49.00 ➝ $28.007/21/2026ACADACADIA Pharmaceuticals BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $36.007/21/2026ACADACADIA Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$24.00 ➝ $25.007/20/2026VKTXViking Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/17/2026SVRASavara Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026VKTXViking Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/13/2026LEGNLegend Biotech JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$35.007/10/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/7/2026LEGNLegend Biotech Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$64.00 ➝ $63.007/7/2026ACADACADIA Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$29.00 ➝ $36.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B3.97$0.89 per share27.99$7.25 per share3.43LEGNLegend Biotech$1.14B3.62N/AN/A$5.43 per share4.09SVRASavaraN/AN/AN/AN/A$1.00 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2011.2925.8817.2234.30%9.61%7.07%8/4/2026 (Confirmed)LEGNLegend Biotech-$296.80M-$0.68N/A14.24N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)SVRASavara-$118.84M-$0.56N/AN/AN/AN/A-87.19%-66.42%8/12/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest SVRA, ACAD, LEGN, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026SVRASavara-$0.14N/AN/AN/A$2.00 millionN/A8/10/2026Q2 2026LEGNLegend Biotech$0.0551N/AN/AN/A$355.40 millionN/A8/4/2026Q2 2026ACADACADIA Pharmaceuticals$0.06N/AN/AN/A$295.51 millionN/A7/29/2026Q2 2026VKTXViking Therapeutics-$1.21N/AN/AN/AN/AN/A5/13/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/12/2026Q1 2026SVRASavara-$0.14-$0.15-$0.01-$0.15$0.50 millionN/A5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48LEGNLegend BiotechN/A2.132.05SVRASavara0.1713.4713.47VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%LEGNLegend Biotech70.89%SVRASavara87.93%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%LEGNLegend Biotech0.02%SVRASavara5.30%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableLEGNLegend Biotech2,965185.74 million185.70 millionOptionableSVRASavara20204.93 million194.07 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableSVRA, ACAD, LEGN, and VKTX HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Increases Stock Position in Viking Therapeutics, Inc. $VKTX4 hours ago | marketbeat.comHere's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketJuly 23 at 10:54 PM | finance.yahoo.comViking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Comes Into ViewJuly 23 at 10:54 PM | finance.yahoo.comViking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy NewsJuly 23 at 10:54 PM | finance.yahoo.comHere's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketJuly 23 at 6:46 PM | zacks.comViking Therapeutics Appoints Dorothy Gemmell to Board of DirectorsJuly 23 at 7:52 AM | finance.yahoo.comViking Therapeutics Appoints Dorothy Gemmell to Board of DirectorsJuly 23 at 7:05 AM | prnewswire.comViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026July 22 at 7:58 PM | finance.yahoo.comViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026July 22 at 4:05 PM | prnewswire.comViking Therapeutics (NASDAQ:VKTX) Rating Lowered to "Strong Sell" at Zacks ResearchJuly 22 at 5:41 AM | marketbeat.comViking Therapeutics (VKTX) to Release Earnings on WednesdayJuly 22 at 4:40 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Crosses Above 50 Day Moving Average - Here's What HappenedJuly 22 at 4:19 AM | marketbeat.comKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmJuly 21, 2026 | prnewswire.comHead-To-Head Analysis: Capstone Therapeutics (NASDAQ:CAPS) vs. Viking Therapeutics (NASDAQ:VKTX)July 21, 2026 | americanbankingnews.comWatch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1July 18, 2026 | fool.comShould You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes.July 18, 2026 | fool.comViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteJuly 17, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteJuly 17, 2026 | zacks.comViking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?July 17, 2026 | finance.yahoo.comViking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?July 17, 2026 | zacks.comThe weight-loss drugs boom is creating both winners and wipeouts: One Big Investment IdeaJuly 17, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSVRA, ACAD, LEGN, and VKTX Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$24.84 +0.01 (+0.04%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$24.84 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Legend Biotech NASDAQ:LEGN$22.22 -1.31 (-5.57%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$22.37 +0.15 (+0.66%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Savara NASDAQ:SVRA$5.51 -0.24 (-4.17%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.51 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Viking Therapeutics NASDAQ:VKTX$34.79 -0.60 (-1.70%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$35.06 +0.27 (+0.76%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
